应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CLYM CLIMB BIO INC
盘前交易 07-10 08:23:55 EDT
1.35
+0.09
+7.14%
最高
1.37
最低
1.25
成交量
59.43万
今开
1.25
昨收
1.26
日振幅
9.52%
总市值
9,123万
流通市值
3,441万
总股本
6,758万
成交额
78.68万
换手率
2.33%
流通股本
2,549万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Climb Bio(CLYM.US)获奥本海默首次覆盖,给予优于大市评级, 目标价10.00美元。
金融界 · 06-06
Climb Bio(CLYM.US)获奥本海默首次覆盖,给予优于大市评级, 目标价10.00美元。
Climb Bio, Inc.2025财年第一财季实现净利润-20.78百万美元,同比减少1122.35%
市场透视 · 05-22
Climb Bio, Inc.2025财年第一财季实现净利润-20.78百万美元,同比减少1122.35%
Climb Bio(CLYM.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.31美元,前值为-0.06美元。
金融界 · 05-14
Climb Bio(CLYM.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.31美元,前值为-0.06美元。
Climb Bio, Inc.2024财年第三财季实现净利润-8.90百万美元,同比减少124.18%
市场透视 · 2024-11-19
Climb Bio, Inc.2024财年第三财季实现净利润-8.90百万美元,同比减少124.18%
加载更多
公司概况
公司名称:
CLIMB BIO INC
所属市场:
NASDAQ
上市日期:
--
主营业务:
Climb Bio, Inc.于2018年10月18日作为特拉华州公司注册成立。该公司是一家生物技术公司,专注于开发神经元兴奋性障碍的新疗法,以解决精神病学、癫痫、慢性疼痛以及外周和中枢神经系统疾病方面未满足的需求。
发行价格:
--
{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":1.35,"timestamp":1752091200000,"preClose":1.26,"halted":0,"volume":594315,"delay":0,"floatShares":25491316,"shares":67575767,"eps":-1.59983,"marketStatus":"盘前交易","change":0.09,"latestTime":"07-10 08:23:55 EDT","open":1.25,"high":1.37,"low":1.25,"amount":786790.331352,"amplitude":0.095238,"askPrice":1.49,"askSize":100,"bidPrice":1.28,"bidSize":2362,"shortable":3,"etf":0,"ttmEps":-1.59983,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752154200000},"marketStatusCode":1,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":1.35,"postHourTrading":{"tag":"盘后","latestPrice":1.3799,"preClose":1.35,"latestTime":"18:20 EDT","volume":1477,"amount":2014.85,"timestamp":1752099651720},"volumeRatio":3.028640645374392},"requestUrl":"/m/hq/s/CLYM","defaultTab":"news","newsList":[{"id":"2541914862","title":"Climb Bio(CLYM.US)获奥本海默首次覆盖,给予优于大市评级, 目标价10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2541914862","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541914862?lang=zh_cn&edition=full","pubTime":"2025-06-07 01:18","pubTimestamp":1749230338,"startTime":"0","endTime":"0","summary":"Climb Bio(CLYM.US)获奥本海默首次覆盖,给予优于大市评级, 目标价10.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/07011850919454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CLYM"],"gpt_icon":0},{"id":"2537923489","title":"Climb Bio, Inc.2025财年第一财季实现净利润-20.78百万美元,同比减少1122.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537923489","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537923489?lang=zh_cn&edition=full","pubTime":"2025-05-23 00:00","pubTimestamp":1747929620,"startTime":"0","endTime":"0","summary":"5月23日,Climb Bio, Inc.公布财报,公告显示公司2025财年第一财季净利润为-20.78百万美元,同比减少1122.35%;其中营业收入为0.00美元,每股基本收益为-0.31美元。从资产负债表来看,Climb Bio, Inc.总负债7.36百万美元,其中短期债务155000.00美元,资产负债比为0.28,流动比率为0.15。机构评级:截至2025年5月23日,当前有1家机构对Climb Bio, Inc.目标价做出预测,其中目标均价为10.00美元,其中最低目标价为10.00美元,最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLYM"],"gpt_icon":0},{"id":"2535028502","title":"Climb Bio(CLYM.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.31美元,前值为-0.06美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535028502","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535028502?lang=zh_cn&edition=full","pubTime":"2025-05-14 19:26","pubTimestamp":1747221969,"startTime":"0","endTime":"0","summary":"Climb Bio(CLYM.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.31美元,前值为-0.06美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/14192650388433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CLYM"],"gpt_icon":0},{"id":"2484991306","title":"Climb Bio, Inc.2024财年第三财季实现净利润-8.90百万美元,同比减少124.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484991306?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010429,"startTime":"0","endTime":"0","summary":"11月19日,Climb Bio, Inc.公布财报,公告显示公司2024财年第三财季净利润为-8.90百万美元,同比减少124.18%;其中营业收入为0.00美元,每股基本收益为-0.13美元。从资产负债表来看,Climb Bio, Inc.总负债3.42百万美元,其中短期债务58000.00美元,资产负债比为0.65,流动比率为0.58。机构评级:截至2024年11月19日,当前有2家机构对Climb Bio, Inc.目标价做出预测,其中目标均价为4.50美元,其中最低目标价为4.00美元,最高目标价为5.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180146a24562b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180146a24562b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLYM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":0.0714},{"period":"1month","weight":0.0075},{"period":"3month","weight":0.1638},{"period":"6month","weight":-0.325},{"period":"1year","weight":-0.7939},{"period":"ytd","weight":-0.25}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1896},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.0648}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Climb Bio, Inc.于2018年10月18日作为特拉华州公司注册成立。该公司是一家生物技术公司,专注于开发神经元兴奋性障碍的新疗法,以解决精神病学、癫痫、慢性疼痛以及外周和中枢神经系统疾病方面未满足的需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.044593},{"month":2,"riseRate":0.5,"avgChangeRate":-0.039153},{"month":3,"riseRate":0.25,"avgChangeRate":-0.102291},{"month":4,"riseRate":0.75,"avgChangeRate":0.286337},{"month":5,"riseRate":0.5,"avgChangeRate":0.027501},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069889},{"month":7,"riseRate":0.75,"avgChangeRate":0.066199},{"month":8,"riseRate":0,"avgChangeRate":-0.068582},{"month":9,"riseRate":0.25,"avgChangeRate":-0.130981},{"month":10,"riseRate":0.25,"avgChangeRate":-0.066822},{"month":11,"riseRate":0,"avgChangeRate":-0.143309},{"month":12,"riseRate":0.5,"avgChangeRate":-0.056887}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CLIMB BIO INC(CLYM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CLIMB BIO INC(CLYM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}